Daniel Goodman, PhD

Postdoctoral Scholar
(co-advised by Alex Marson and Kole Roybal)
Diabetes Center

Immune receptors are surprisingly modular and can be mutated and composed to rewire cellular inputs and outputs, as showcased by the success of cell-based genetic therapies like Chimeric Antigen Receptor T-cell (CAR-T) therapy. My work involves high-throughput pooled screening of millions of different synthetic receptors. A better understanding of the relationship between receptor sequence, signaling outcome, and cellular phenotype will lead to next-generation cell-based genetic therapies which manipulate the immune system to combat a variety of diseases.